XSHG600829
Market cap620mUSD
Dec 24, Last price
7.88CNY
1D
-4.64%
1Q
45.17%
Jan 2017
-48.89%
Name
HPGC Renmintongtai Pharmaceutical Corp
Chart & Performance
Profile
HPGC Renmintongtai Pharmaceutical Corporation engages in the wholesale and retail of pharmaceutical products in China and internationally. The company offers Chinese medicines, Chinese herbal medicine, chemical preparations, antibiotics, biological products, and biochemical drugs, as well as medical equipment and health products. It also provides logistics services, including warehousing and distribution; and hospital services comprising medical treatment, scientific research, prevention, health care, rehabilitation, blood purification, and renal disease treatment. In addition, the company offers Chinese and Western medicines, Chinese herbal medicines, nourishing health care products, medical equipment, cosmetics, and daily necessities through an e-commerce platform. It operates 319 chain stores in Heilongjiang Province. The company was founded in 1950 and is headquartered in Harbin, China. HPGC Renmintongtai Pharmaceutical Corporation is a subsidiary of Harbin Pharmaceutical Group Co., Ltd.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | 2014‑12 | |
Income | ||||||||||
Revenues | 10,389,980 7.77% | 9,641,093 3.50% | 9,315,236 16.36% | |||||||
Cost of revenue | 9,517,523 | 9,157,795 | 8,784,483 | |||||||
Unusual Expense (Income) | ||||||||||
NOPBT | 872,457 | 483,298 | 530,753 | |||||||
NOPBT Margin | 8.40% | 5.01% | 5.70% | |||||||
Operating Taxes | 101,138 | 82,148 | 82,091 | |||||||
Tax Rate | 11.59% | 17.00% | 15.47% | |||||||
NOPAT | 771,320 | 401,150 | 448,662 | |||||||
Net income | 292,162 10.47% | 264,478 -4.62% | 277,296 90.89% | |||||||
Dividends | (24,621) | (69,587) | ||||||||
Dividend yield | 0.54% | 1.79% | ||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
Debt | ||||||||||
Debt current | 962,080 | 1,229,886 | 1,267,984 | |||||||
Long-term debt | 58,818 | 76,963 | 119,171 | |||||||
Deferred revenue | 125,707 | 130,771 | ||||||||
Other long-term liabilities | 121,088 | 566 | 1,563 | |||||||
Net debt | (333,218) | 84,839 | 543,524 | |||||||
Cash flow | ||||||||||
Cash from operating activities | 332,986 | 307,328 | ||||||||
CAPEX | (23,484) | |||||||||
Cash from investing activities | (179,858) | |||||||||
Cash from financing activities | 117,858 | 149,513 | 342,311 | |||||||
FCF | 779,838 | 576,851 | (79,123) | |||||||
Balance | ||||||||||
Cash | 1,314,347 | 1,181,469 | 800,492 | |||||||
Long term investments | 39,769 | 40,540 | 43,139 | |||||||
Excess cash | 834,617 | 739,955 | 377,869 | |||||||
Stockholders' equity | 2,751,375 | 2,463,698 | 2,200,251 | |||||||
Invested Capital | 3,029,336 | 3,065,349 | 3,233,373 | |||||||
ROIC | 25.31% | 12.74% | 15.09% | |||||||
ROCE | 22.56% | 12.70% | 14.70% | |||||||
EV | ||||||||||
Common stock shares outstanding | 579,916 | 579,889 | 579,889 | |||||||
Price | 7.82 22.57% | 6.38 -5.06% | 6.72 -9.43% | |||||||
Market cap | 4,534,945 22.58% | 3,699,689 -5.06% | 3,896,851 -9.43% | |||||||
EV | 4,201,684 | 3,784,528 | 4,440,376 | |||||||
EBITDA | 934,917 | 547,290 | 591,191 | |||||||
EV/EBITDA | 4.49 | 6.92 | 7.51 | |||||||
Interest | 36,339 | 44,423 | 50,317 | |||||||
Interest/NOPBT | 4.17% | 9.19% | 9.48% |